Featured Articles
FORMULATION FORUM - LIPIDSOL®: Liposomes - Chemistry, Properties & Applications of Lipid Nanoparticles
Jim Huang, PhD, and Shaukat Ali, PhD, describe their LNP platform as well as the latest trends in LNPs as more and more novel therapeutic modalities discovered can’t be handled by traditional microemulsions or nanoemulsions.
SPECIAL FEATURE - Parenteral Drug Delivery: Could a Dose of AI Improve Development?
Contributor Cindy H. Dubin speaks with several innovative companies to highlight the strides they are currently making toward improving dose accuracy, integrating design safety, and accelerating time to market.
IMMUNOLOGY - Innovation Gathers Momentum Amid New Scientific & Technological Breakthroughs
Patrick Larcier, PhD, says research is entering a new era in immunology with treatments for pathologies that previously had few or no options and looks at the latest trends and what is on the horizon for 2023 and beyond.
ION EXCHANGE EXCIPIENTS - Tackling Patient Compliance With Oral Drug Formulations Using Ion Exchange Resins
Amie Gehris explains how IERs solve various pharmaceutical formulation issues, including decreasing the bitter taste of many pharmaceutical drugs, improving patient outcomes by supporting compliance to treatment regimens, and providing new revenue streams for pharmaceutical companies.
DELIVERY DEVICES - Growing Connected Market Set to Elevate Healthcare Outcomes
Michael Earl examines what the connected device market will look to achieve in the coming years and how it is likely to drive improved adherence to treatments and improve overall healthcare outcomes.
EXECUTIVE INTERVIEW - Novadip Biosciences: Developing a New Class of Regenerative Tissue Products to Accelerate Healing of Critical Size Bone Defects, Trauma & Spinal Problems
Denis Dufrane, MD, PhD, Chief Executive Officer, and Founder of Novadip Biosciences, discusses his company’s innovative approach to tissue regeneration technology.
DRUG-ELUTING SYSTEMS - Introducing Drugs to Silicone & Controlling Elution Rates
Zach Fletcher explains how an experienced manufacturing partner can help therapy developers quickly identify solutions and develop manufacturing and formulation methods for use in many applications.
EXECUTIVE INTERVIEW - Ascendia Pharmaceuticals: Innovative Solutions to Challenging Problems
Jim Huang, PhD, CEO and Founder of Ascendia Pharmaceuticals, discusses how his company expanded its people, capabilities, and facilities to meet and exceed customer expectations from early to late-state development and how this investment allows Ascendia to continue be an expert in sophisticated formulations, as well as cGMP sterile and non-sterile clinical trial and commercial manufacturing.
VACCINE TECHNOLOGY - Solving the Challenges & Introducing New Strategies for Influenza & COVID-19 Protection
Paul Radspinner, MBA, and Pamuk Bilsel, PhD, say with a combination vaccination strategy, the biopharma industry could truly solve the efficacy, durability, and drift problems of current influenza and COVID-19 vaccines.
(e-book) The Oral Dosage Drug Delivery Market 2023
Place Your Oral Formulation In Experienced Hands Download: The Oral Dosage Drug Delivery Market. Thank you for your interest in Pii and our eBook on…
INFLAMMASOME INHIBITORS - 21st Century Miracle Drugs: Spotlight on Clinical NLRP3 Inflammasome Inhibitors
Bryan Oronsky, PhD, says traditionally, pharmaceutical development is based on the “magic bullet” concept of “one drug, one target, one disease.” However, with the growing realization that chronic inflammation lies at the center of many, if not all, diseases, it is possible to envision inflammasome inhibitors, which reduce or prevent inflammation, as near-universal treatment panaceas.
SPECIAL FEATURE - Excipients: Their Future Could Lie in Generics
Contributor Cindy H. Dubin highlights the innovative work being done by several leading companies and exemplifies the importance of excipients to the future of drug development.
FORMULATION FORUM - Tackling Challenging Molecules by Spray Drying: Making the Impossible Possible
Jim Huang, PhD, and Shaukat Ali, PhD, focus on spray drying technology with special reference to polymers and solvents selection, processing conditions, and the challenges with downstream manufacturing, stability, and degradation of APIs in oral dosages.
EXECUTIVE INTERVIEW - PCI Pharma Services: The Global, Integrated CDMO Partner of Choice
John Ross, Senior Vice President of Development and Manufacturing at PCI Pharma Services, discusses what it means to be the partner of choice in a very dynamic industry.
MICROCRYSTALLINE CELLULOSE - N-nitrosamine Risk Assessments for Oral Dosage Forms
Takako Koyamatsu, Shohei Mikami, PharmD, Obata Kenji, and Julia Shmyrova show how Ceolus™ demonstrated a very low level of nitrite and nitrate that can allow mitigating nitrosamine formation in the drug products with secondary or tertiary amines.
DRUG-ELUTING IMPLANTS - Delivery of RNAi Therapeutics Through Drug-Eluting Implants
Cyonna Holmes, PhD, Karen Chen, MS, and Brian Wilson, PhD, review how localized therapeutic delivery of these therapies through an implant provides an innovative route of administration for chronic conditions that are difficult to dose adequately.
MARKET TRENDS - The Year of Resilience & Flexibility: Six Smart Ways CDMOs Are Preparing for 2023
Carsten Press says with biopharma businesses weathering one unexpected shift after another, it’s no surprise these organizations are looking to their partner networks for one thing above all: the flexibility they need to maximize their own business resilience.
LIPID-BASED EXCIPIENTS - Misconceptions About Lipid-Based Drug Delivery
Rollie Fuller and Ron Permutt provide formulators confidence in using LBDDS as part of formulation development programs, by demonstrating their benefits and key functional mechanisms when used and addressing commonly misrepresented, misinterpreted, and misunderstood LBDDS topics.
BIOAVAILABILITY ENHANCEMENT - Solving Low Solubility Challenges to Optimize Drug Delivery Platforms
David K. Lyon, PhD, discusses how low aqueous solubility NCEs have come to define the innovative pharmaceutical pipelines and how advanced technologies are often required to overcome this issue.
PLATFORM TECHNOLOGY - An Alternative Solution for Peptide Drug Formulation
Michael Neely introduces a unique technology platform and provides examples of how it has solved difficult formulation problems while adding significant commercial value to the resulting drug products.
